{"id":28308,"date":"2024-06-14T14:54:05","date_gmt":"2024-06-14T09:24:05","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=28308"},"modified":"2024-09-23T17:05:02","modified_gmt":"2024-09-23T11:35:02","slug":"opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market","title":{"rendered":"OPDIVO vs. KEYTRUDA: The Battle for Japan\u2019s PD-1 Inhibitor Market Dominance"},"content":{"rendered":"\n

Bristol Myers Squibb\u2019s PD-1 inhibitor, OPDIVO<\/strong>, has deep roots in Japan. In July 2014, MHLW approved OPDIVO to treat melanoma, marking it the first approved PD-1 inhibitor globally. About two years later, KEYTRUDA <\/strong>gained approval in Japan for the same indications (melanoma and NSCLC). This set the stage for fierce competition between OPDIVO and KEYTRUDA, as both vied to become Japan\u2019s top-selling PD-1 inhibitor<\/a>. <\/p>\n\n\n\n

Analyzing OPDIVO\u2019s Pre-2022 Sales Decline and KEYTRUDA\u2019s Market Ascendancy<\/strong><\/h2>\n\n\n\n

KEYTRUDA and OPDIVO have received approval for 12 indications in Japan, with 8 of these indications being common to both drugs.<\/p>\n\n\n\n

<\/span><\/p>\n

\n<\/colgroup>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

First approval of KEYTRUDA and OPDIVO in Japan for their respective indications<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

KEYTRUDA<\/span><\/p>\n<\/td>\n

\n

OPDIVO<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Indication<\/span><\/p>\n<\/td>\n

\n

Approval Year<\/span><\/p>\n<\/td>\n

\n

Indication<\/span><\/p>\n<\/td>\n

\n

Approval Year<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Melanoma<\/span><\/p>\n<\/td>\n

\n

2016<\/span><\/p>\n<\/td>\n

\n

Melanoma<\/span><\/p>\n<\/td>\n

\n

2014<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

NSCLC<\/span><\/p>\n<\/td>\n

\n

2016<\/span><\/p>\n<\/td>\n

\n

NSCLC<\/span><\/p>\n<\/td>\n

\n

2015<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Classical Hodgkin Lymphoma (cHL)<\/span><\/p>\n<\/td>\n

\n

2017<\/span><\/p>\n<\/td>\n

\n

Renal Cell Carcinoma (RCC)<\/span><\/p>\n<\/td>\n

\n

2016<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Urothelial Carcinoma<\/span><\/p>\n<\/td>\n

\n

2017<\/span><\/p>\n<\/td>\n

\n

Classical Hodgkin Lymphoma (cHL)<\/span><\/p>\n<\/td>\n

\n

2016<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Head and neck squamous cell carcinoma (HNSCC)<\/span><\/p>\n<\/td>\n

\n

2019<\/span><\/p>\n<\/td>\n

\n

Head and neck squamous cell carcinoma (HNSCC)<\/span><\/p>\n<\/td>\n

\n

2017<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Renal cell carcinoma (RCC)<\/span><\/p>\n<\/td>\n

\n

2019<\/span><\/p>\n<\/td>\n

\n

Gastric Cancer<\/span><\/p>\n<\/td>\n

\n

2017<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Esophageal cancer<\/span><\/p>\n<\/td>\n

\n

2020<\/span><\/p>\n<\/td>\n

\n

Esophageal Cancer<\/span><\/p>\n<\/td>\n

\n

2020<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Colorectal cancer<\/span><\/p>\n<\/td>\n

\n

2021<\/span><\/p>\n<\/td>\n

\n

Colorectal Cancer<\/span><\/p>\n<\/td>\n

\n

2020<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Triple-negative breast cancer (TNBC)<\/span><\/p>\n<\/td>\n

\n

2021<\/span><\/p>\n<\/td>\n

\n

Cancer of Unknown Primary<\/span><\/p>\n<\/td>\n

\n

2021<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Endometrial cancer<\/span><\/p>\n<\/td>\n

\n

2021<\/span><\/p>\n<\/td>\n

\n

Urothelial Carcinoma<\/span><\/p>\n<\/td>\n

\n

2022<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Cervical cancer<\/span><\/p>\n<\/td>\n

\n

2022<\/span><\/p>\n<\/td>\n

\n

Malignant mesothelioma<\/span><\/p>\n<\/td>\n

\n

2023<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Non-Hodgkin’s lymphoma (NHL)<\/span><\/p>\n<\/td>\n

\n

2023<\/span><\/p>\n<\/td>\n

\n

Epithelial Tumors<\/span><\/p>\n<\/td>\n

\n

2024<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n

As the first PD-1 inhibitor<\/a> approved in Japan and worldwide, OPDIVO secured six approvals by 2017, including for melanoma, NSCLC, RCC, cHL, HNSCC, and gastric cancer. Meanwhile, KEYTRUDA only received approvals for four indications: melanoma, NSCLC, cHL, and urothelial carcinoma. OPDIVO initially dominated the PD-(L)1 market in Japan, benefiting from its earlier approval. However, this led to a significant development in October 2016 when Chuikyo\u2019s drug pricing subcommittee approved an emergency price reduction for OPDIVO. This unprecedented decision resulted in a major price cut in November 2016, an exceptional move in procedural terms. Traditionally, drug prices were reviewed biennially alongside medical service fee revisions, but OPDIVO underwent an urgent repricing process specifically targeting this drug. This process resulted in a substantial reduction in February 2017 under the market expansion repricing system. Further recalculations due to changes in indication and dosage led to additional price cuts in 2018, significantly impacting its sales trajectory.<\/p>\n\n\n\n

Another factor contributing to OPDIVO\u2019s decline was its approval in multiple indications within smaller subsegments. Within NSCLC<\/a>, OPDIVO was approved for second-line treatment in 2015, and it took another 5 years before it received approval for first-line treatment in Japan. In contrast, KEYTRUDA targeted larger patient populations more effectively. Merck strategically focused on NSCLC, securing approvals both as a monotherapy and in combination therapies. KEYTRUDA was approved for first-line and second-line treatment in 2016. In 2018, it also received approvals for first-line treatment in combination with chemotherapy for non-squamous, squamous, and Stage III NSCLC, significantly boosting its sales.<\/p>\n\n\n\n

Merck\u2019s commitment to KEYTRUDA included substantial investments to enhance its pipeline, such as acquiring biotech companies with valuable expertise. By prioritizing collaborations that integrated PD-1 inhibitor drugs<\/a> into clinical trials as part of combination therapies, Merck improved their commercial development and secured a greater number of indication approvals, reinforcing KEYTRUDA\u2019s dominant position in the market.<\/p>\n\n\n\n

\"Market<\/figure>\n\n\n\n

How OPDIVO Outpaced KEYTRUDA in Japan\u2019s Pharmaceutical Market<\/strong><\/h2>\n\n\n\n

In 2021, Merck\u2019s KEYTRUDA and Ono Pharmaceutical’s OPDIVO vied for dominance in Japan’s pharmaceutical sales, with both drugs achieving comparable revenue figures despite quarterly pricing challenges. However, in 2022, OPDIVO surged ahead to claim the top spot in sales, outpacing KEYTRUDA by a significant margin.<\/p>\n\n\n\n

OPDIVO\u2019s remarkable sales growth in 2022 was fueled by its expanded label in RCC, GEJ Cancer, cancer of unknown primary, and cHL. Gastric cancer is more prevalent in Japan, with approximately 140,000 cases annually, further bolstering OPDIVO’s position, especially since KEYTRUDA lacked approval for gastric cancer<\/a>.<\/p>\n\n\n\n

Recognizing the unique market dynamics, Ono Pharmaceutical strategically focused on developing OPDIVO for specific indications prevalent in Japan and East Asia, including gastrointestinal cancers, stomach cancers, liver cancers, colorectal cancers, and esophageal cancers. This targeted approach enabled OPDIVO to reclaim its leadership in Japan\u2019s pharmaceutical landscape. Meanwhile, KEYTRUDA’s strength remains in markets where it is the preferred choice, especially for NSCLC in Western countries. The company\u2019s strategy to maintain its dominance in these areas shows a deep understanding of regional preferences and disease patterns, keeping it competitive despite OPDIVO’s success in Japan.<\/p>\n\n\n\n

Clash of Titans: The Fierce Battle between KEYTRUDA and OPDIVO in Japan’s Cancer Market<\/strong><\/h2>\n\n\n\n

In the upcoming years, Merck plans to expand the use of KEYTRUDA by launching it in combination with chemotherapy, vibostolimab \u00b1 chemotherapy for NSCLC, SCLC, and melanoma in neoadjuvant\/adjuvant, 1L, and 2L+ settings. Additionally, Merck is targeting gastric cancer with KEYTRUDA combined with trastuzumab and chemotherapy for HER2+ and KEYTRUDA with chemotherapy for HER2- gastric cancer. Beyond these indications, Merck is conducting over 30 trials in Japan for KEYTRUDA, both as a monotherapy and in combinations.<\/p>\n\n\n\n

However, OPDIVO is not far behind. Ono Pharmaceutical and Bristol Myers Squibb are also conducting multiple combination trials, including with YERVOY in gastric cancer, NSCLC, HCC, and CRC, with relatlimab in melanoma, and with chemotherapy in urothelial cancer. Many of Ono\u2019s trials focus on the adjuvant setting to capture a larger patient share.<\/p>\n\n\n\n

The competition between KEYTRUDA and OPDIVO remains intense. Historically, the lead has shifted between the two, with OPDIVO currently holding the top position. This ongoing battle will depend heavily on each company\u2019s strategies, launch timings, and promotional efforts. With an expected expansion in different indications along with different settings, the leadership in this PD-(L)1 inhibitor market<\/a> can change from year to year, reflecting the dynamic nature of their competitive strategies.<\/p>\n\n\n\n

\"PD-L1-Inhibitors-Market-Outlook\"<\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"

Bristol Myers Squibb\u2019s PD-1 inhibitor, OPDIVO, has deep roots in Japan. In July 2014, MHLW approved OPDIVO to treat melanoma, marking it the first approved PD-1 inhibitor globally. About two years later, KEYTRUDA gained approval in Japan for the same indications (melanoma and NSCLC). This set the stage for fierce competition between OPDIVO and KEYTRUDA, […]<\/p>\n","protected":false},"author":14,"featured_media":28312,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[345,431,22125,22126,454,456,3069,22148,22130,22127,457],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-28308","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-keytruda","tag-opdivo","tag-pd-l1-inhibitors","tag-pd-l1-market","tag-pd-1-and-pd-l-1-inhibitors","tag-pd-1-and-pd-l1-inhibitors","tag-pd-1-inhibitor","tag-pd-1-inhibitor-market","tag-pd-1-l1-inhibitor","tag-pd-1-pd-l1","tag-pd-1pdl-1","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nJapan\u2019s PD-1 Inhibitor Market: OPDIVO versus KEYTRUDA<\/title>\n<meta name=\"description\" content=\"Competition between KEYTRUDA and OPDIVO remains intense. Historically, lead has shifted, with OPDIVO currently holding top position\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Japan\u2019s PD-1 Inhibitor Market: OPDIVO versus KEYTRUDA\" \/>\n<meta property=\"og:description\" content=\"Competition between KEYTRUDA and OPDIVO remains intense. Historically, lead has shifted, with OPDIVO currently holding top position\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-14T09:24:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T11:35:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/14145318\/opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Japan\u2019s PD-1 Inhibitor Market: OPDIVO versus KEYTRUDA","description":"Competition between KEYTRUDA and OPDIVO remains intense. Historically, lead has shifted, with OPDIVO currently holding top position","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market","og_locale":"en_US","og_type":"article","og_title":"Japan\u2019s PD-1 Inhibitor Market: OPDIVO versus KEYTRUDA","og_description":"Competition between KEYTRUDA and OPDIVO remains intense. Historically, lead has shifted, with OPDIVO currently holding top position","og_url":"https:\/\/www.delveinsight.com\/blog\/opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-06-14T09:24:05+00:00","article_modified_time":"2024-09-23T11:35:02+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/14145318\/opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market","url":"https:\/\/www.delveinsight.com\/blog\/opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market","name":"Japan\u2019s PD-1 Inhibitor Market: OPDIVO versus KEYTRUDA","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/14145318\/opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market.png","datePublished":"2024-06-14T09:24:05+00:00","dateModified":"2024-09-23T11:35:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Competition between KEYTRUDA and OPDIVO remains intense. Historically, lead has shifted, with OPDIVO currently holding top position","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/14145318\/opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/14145318\/opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market.png","width":466,"height":284,"caption":"opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/14145318\/opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Keytruda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Opdivo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-(L)1 Inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-(L)1 market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1 and PD-L 1 inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1 and PD-L1 inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1 inhibitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1 Inhibitor Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1\/L1 inhibitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1\/PD-L1<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1\/PDL-1<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Keytruda<\/span>","<span class=\"advgb-post-tax-term\">Opdivo<\/span>","<span class=\"advgb-post-tax-term\">PD-(L)1 Inhibitors<\/span>","<span class=\"advgb-post-tax-term\">PD-(L)1 market<\/span>","<span class=\"advgb-post-tax-term\">PD-1 and PD-L 1 inhibitors<\/span>","<span class=\"advgb-post-tax-term\">PD-1 and PD-L1 inhibitors<\/span>","<span class=\"advgb-post-tax-term\">PD-1 inhibitor<\/span>","<span class=\"advgb-post-tax-term\">PD-1 Inhibitor Market<\/span>","<span class=\"advgb-post-tax-term\">PD-1\/L1 inhibitor<\/span>","<span class=\"advgb-post-tax-term\">PD-1\/PD-L1<\/span>","<span class=\"advgb-post-tax-term\">PD-1\/PDL-1<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Jun 14, 2024","modified":"Updated on Sep 23, 2024"},"absolute_dates_time":{"created":"Posted on Jun 14, 2024 2:54 pm","modified":"Updated on Sep 23, 2024 5:05 pm"},"featured_img_caption":"opdivo-vs-keytruda-in-japans-pd-1-inhibitor-market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=28308"}],"version-history":[{"count":5,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28308\/revisions"}],"predecessor-version":[{"id":29706,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28308\/revisions\/29706"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/28312"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=28308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=28308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=28308"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=28308"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=28308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}